- Home
- WHWK vs GANX Comparison
WHWK vs GANX Comparison
Compare WHWK & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHWK
- GANX
- Stock Information
- Founded
- WHWK 2007
- GANX 2017
- Country
- WHWK United States
- GANX United States
- Employees
- WHWK N/A
- GANX N/A
- Industry
- WHWK Biotechnology: Pharmaceutical Preparations
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- WHWK Health Care
- GANX Health Care
- Exchange
- WHWK Nasdaq
- GANX Nasdaq
- Market Cap
- WHWK 48.3M
- GANX 45.8M
- IPO Year
- WHWK N/A
- GANX 2021
- Fundamental
- Price
- WHWK $1.54
- GANX $1.85
- Analyst Decision
- WHWK
- GANX Strong Buy
- Analyst Count
- WHWK 0
- GANX 6
- Target Price
- WHWK N/A
- GANX $8.33
- AVG Volume (30 Days)
- WHWK 103.9K
- GANX 272.1K
- Earning Date
- WHWK 05-15-2025
- GANX 05-13-2025
- Dividend Yield
- WHWK N/A
- GANX N/A
- EPS Growth
- WHWK N/A
- GANX N/A
- EPS
- WHWK N/A
- GANX N/A
- Revenue
- WHWK $25,983,000.00
- GANX N/A
- Revenue This Year
- WHWK $96.28
- GANX N/A
- Revenue Next Year
- WHWK N/A
- GANX N/A
- P/E Ratio
- WHWK N/A
- GANX N/A
- Revenue Growth
- WHWK 6.69
- GANX N/A
- 52 Week Low
- WHWK $1.21
- GANX $0.89
- 52 Week High
- WHWK $3.81
- GANX $3.65
- Technical
- Relative Strength Index (RSI)
- WHWK N/A
- GANX 48.82
- Support Level
- WHWK N/A
- GANX $1.67
- Resistance Level
- WHWK N/A
- GANX $1.82
- Average True Range (ATR)
- WHWK 0.00
- GANX 0.18
- MACD
- WHWK 0.00
- GANX 0.02
- Stochastic Oscillator
- WHWK 0.00
- GANX 74.30
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.